Fig. 2

MiR-31 negatively regulates the expression of LATS2 by directly targeting the LATS2 3′-UTR. a Schematic representation of miR-31 gene promoter with the putative LATS2-binding sites and the sequences of the point mutations. b Luciferase activity in cells following co-transfection with control or miR-31-encoding plasmids and wild or mutant LATS2 pLUC vectors to predict miR-31 binding site in the 3′-UTR of LATS2. c-d. The mRNA and protein levels of LATS2 were detected in the group of ESCC cell lines than HEEC cell lines via qRT-PCR and western blot assays. e-f. QRT-PCR and western blot analysis showed that miR-31 could negatively regulate LATS2 expression of ESCC cells. g. Immunohistochemical staining of LATS2 protein in primary ESCC tissue samples (Left: ×200; Right: ×400). h-i. Kaplan-Meier survival plots analysis of the association of LATS2 with the OS and PFS of ESCC patients. Values are mean ± SD; *: P < 0.05; **: P < 0.01